 Gossamer Bio, Inc. Nasdaq: GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and biomarker data at the 2020 American Society of Clinical Oncology Virtual Scientific Program ASCO20 from its ongoing Phase 12 study of GB1275 in patients with selected solid tumors. 